Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “PD-1 Antibodies”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableUnknownNCT05821192
What this trial is testing

Chemotherapy Plus PD-1 Monoclonal Antibody in the Treatment of Refractory or Relapsed Peripheral T-cell Lymphoma.

Who this might be right for
Peripheral T-Cell Lymphoma, Not Otherwise SpecifiedAngioimmunoblastic T-cell Lymphoma
Ou Bai, MD/PHD 34
Testing effectiveness (Phase 2)Looking for participantsNCT06484153
What this trial is testing

Fruquintinib and Pirfenidone in Combination With Anti-PD-1 Antibody in Advanced or Metastatic pMMR/MSS Colorectal Carcinoma

Who this might be right for
To Evaluate the Efficacy of Fruquintinib and Pirfenidone in Combination With Anti-PD-1 Antibody in Colorectal CarcinomaTo Evaluate Whether Pirfenidone Can Reshape the Tumor Microenvironment in Colorectal CancerCombination of Fruquintinib and Anti-PD-1 Antibody Was Reported to Improve Patient Prognosis in Colorectal Cancer
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Early research (Phase 1)Looking for participantsNCT05112549
What this trial is testing

Intrathecal Application of PD1 Antibody in Metastatic Solid Tumors With Leptomeningeal Disease (IT-PD1/ NOA 26)

Who this might be right for
Leptomeningeal Disease
University Hospital Tuebingen 46
Testing effectiveness (Phase 2)Active Not RecruitingNCT04718415
What this trial is testing

Neoadjuvant Sintilimab in Combination With Carboplatin and Nab-paclitaxel in Resectable Oral Cavity or Oropharyngeal Squamous Cell Carcinoma

Who this might be right for
Oral Squamous Cell CarcinomaOropharyngeal Squamous Cell Carcinoma
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 51
Testing effectiveness (Phase 2)Study completedNCT03419897
What this trial is testing

Study of BGB-A317 in Participants With Previously Treated Unresectable HCC

Who this might be right for
Hepatocellular Carcinoma (HCC)
BeiGene 249
Not applicableLooking for participantsNCT06537908
What this trial is testing

Anti-PD-1/PD-L1 Antibodies Plus Anti-VEGF Antibody Treatment in Patients With Advanced-Stage HCC

Who this might be right for
Hepatocellular Carcinoma
Shanghai Zhongshan Hospital 50
Testing effectiveness (Phase 2)Not Yet RecruitingNCT05502991
What this trial is testing

Sintilimab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for ctDNA-level-relapse and Clinical-relapse Glioblastoma

Who this might be right for
Glioblastoma
Henan Provincial People's Hospital 60
Not applicableLooking for participantsNCT06102759
What this trial is testing

Adebrelimab and Fruquintinib Combined With Paclitaxel/Albumin Paclitaxel for Advanced Gastric Cancer After PD-1 Antibody Failed

Who this might be right for
Gastric Cancer
Tianjin Medical University Cancer Institute and Hospital 30
Not applicableUnknownNCT05841342
What this trial is testing

Prospective Study of Immune Function and PD-1 Antibody Therapy Efficacy Predictors on CAEBV and EBV-HLH Patients

Who this might be right for
Secondary Hemophagocytic LymphohistiocytosisChronic Active Epstein-Barr Virus Infection
Beijing Friendship Hospital 128
Testing effectiveness (Phase 2)UnknownNCT04133337
What this trial is testing

Apatinib Combined With SHR-1210 Injection in the Treatment of Patients With Removable IB-IIIA NSCLC

Who this might be right for
Lung DiseasesNeoplasmsRespiratory Tract Diseases+2 more
Sichuan Cancer Hospital and Research Institute 20
Testing effectiveness (Phase 2)UnknownNCT06206096
What this trial is testing

PD-1 Antibody Plus Bevacizumab and CAPOX as First-line Treatment for RAS-mut MSS mCRC

Who this might be right for
Colorectal CancerRAS MutationColorectal Neoplasms+1 more
Chinese PLA General Hospital 40
Testing effectiveness (Phase 2)Looking for participantsNCT07646639
What this trial is testing

Different-Dose SCRT Plus CAPOX, PD-1 Blockade and IL-2 in LARC

Who this might be right for
Rectal CancerRadiotherapy
The First Affiliated Hospital with Nanjing Medical University 122
Testing effectiveness (Phase 2)Ended earlyNCT03071094
What this trial is testing

A Trial to Evaluate the Safety and Efficacy of the Combination of the Oncolytic Immunotherapy Pexa-Vec With the PD-1 Receptor Blocking Antibody Nivolumab in the First-line Treatment of Advanced Hepatocellular Carcinoma (HCC)

Who this might be right for
Hepatocellular Carcinoma (HCC)
Transgene 14
Testing effectiveness (Phase 2)Study completedNCT03878472
What this trial is testing

Neoadjuvant Immunotherapy for Resectable Gastric Cancer

Who this might be right for
Gastric Cancer
Qilu Hospital of Shandong University 25
Testing effectiveness (Phase 2)Study completedNCT05773105
What this trial is testing

Cadonilimab Combined With Regorafenib in Patients With Advanced HCC

Who this might be right for
Advanced Hepatocellular Carcinoma
Sun Yat-sen University 36
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06586294
What this trial is testing

Anti-PD-1 and LAG-3 Bispecific Antibody(AK129) Combined With Chemotherapy With or Without Cadonilimab in the First-line Treatment of Unresectable Locally Advanced or Metastatic G/ GEJ Adenocarcinoma

Who this might be right for
Gastric AdenocarcinomaGastroesophageal Junction Adenocarcinoma
Akeso 294
Large-scale testing (Phase 3)Looking for participantsNCT05738694
What this trial is testing

Neoadjuvant of Axitinib Plus PD-1 to Improve Disease Free Survival of Patients With Renal Cell Carcinoma

Who this might be right for
Renal Cell CarcinomaNeoadjuvant
ZHOU FANGJIAN 298
Early research (Phase 1)Temporarily pausedNCT07176975
What this trial is testing

Test How Well Different Doses of BI 1831169 in Combination With an Anti-PD1 Antibody Are Tolerated in Japanese People With Different Advanced Cancers

Who this might be right for
Solid Tumors
Boehringer Ingelheim 46
Large-scale testing (Phase 3)Not Yet RecruitingNCT04301739
What this trial is testing

To Evaluate Efficacy and Safety of HLX10 in Combination With Chemotherapy Versus Placebo in Combination With Chemotherapy as Neoadjuvant Therapy and HLX10 Versus Placebo as Adjuvant Therapy in Patients With Triple Negative Breast Cancer (TNBC)

Who this might be right for
Triple Negative Breast Cancer
Shanghai Henlius Biotech 522
Not applicableLooking for participantsNCT06549907
What this trial is testing

A Biomarker Exploratory Study of Dual Blockade of PD1/PDL1 and CTLA4 and Anti-angiogenic Therapy

Who this might be right for
MSS Metastatic Colorectal CancersMSI Solid Tumors Refractory to PD1/PDL1 Antibody Monotherapy
Peking University Cancer Hospital & Institute 50
Next Page
25